Tumors
Conditions
Keywords
Positron Emission Tomography, Fluorodeoxyglucose, FDG (18F-Fluorodeoxyglucose), Oncology, Neurology
Brief summary
This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.
Interventions
RADIATION[18F]-Fluorodeoxyglucose
With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
Sponsors
Winnipeg Regional Health Authority
University of Manitoba
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Known or suspected primary or metastatic tumours * A neurological presentation consistent with the list of indications * 18 years of age or older of either sex * Able to provide written informed consent * Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan * Karnofsky score \> 60 * Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours
Exclusion criteria
* Age \<18 years * Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status * Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18F-Fluorodeoxyglucose(FDG) administration * Subjects who are medically unstable * Subjects unwilling to provide informed consent. * Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis. | Three years | The primary outcomes of sensitivity and accuracy of 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) studies will be obtained by comparing results of the PET scan with the gold standard of histopathological diagnosis when those results are available. Comparison to correlative imaging follow-up, and assessment of efficacy based on feedback from referring physicians will be used in the absence of pathologic data. |
Countries
Canada
Outcome results
None listed